Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
- Share Price (Ordinary Shares): 1,463 pence
- Share Price (ADS): $47.45
- Transaction Type: Notional re-investment of dividends paid on October 4, 2012.
Material Changes
The filing reports increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for various executives following the dividend re-investment. No material changes to the company's financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors
- The filing confirms the re-investment of dividends for the GlaxoSmithKline Performance Share Plan on October 9, 2012.
- Transactions were executed at a price of 1,463 pence per Ordinary Share and $47.45 per ADS.
- Specific notional share increases were recorded for 16 named executives, including Sir Andrew Witty (17,794.388 Ordinary Shares) and Dr M M Slaoui (5,117.213 ADSs).
- This report is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a) and does not contain financial performance data.